Conatumumab

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.[1][2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[3][4]

Conatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTRAIL-R2 (CD262)
Clinical data
Other namesanti-TRAIL receptor 2 monoclonal antibody, AMG-655
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6466H10006N1730O2024S40
Molar mass145645.66 g·mol−1
 NY (what is this?)  (verify)

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References

  1. Rosevear HM, Lightfoot AJ, Griffith TS (June 2010). "Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer". Current Opinion in Investigational Drugs. London, England. 11 (6): 688–98. PMID 20496264.
  2. Bajaj M, Heath EI (November 2011). "Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults". Expert Opinion on Biological Therapy. 11 (11): 1519–24. doi:10.1517/14712598.2011.610788. PMID 21877997. S2CID 28520935.
  3. Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
  4. National Cancer Institute: Definition of conatumomab


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.